Results 11 to 20 of about 11,489 (193)

MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. [PDF]

Immunol Res, 2009
Human infections with highly pathogenic avian influenza viruses of the H5N1 subtype, frequently reported since 2003, result in high morbidity and mortality.
Amerongen, Geert van, Brand, Judith M. A. van den, Fouchier, Ron A. M., Kreijtz, Joost H. C. M., Löwer, Johannes, Mutsert, Gerrie de, Osterhaus, Albert D. M. E., Rimmelzwaan, Guus F., Schwantes, Astrid, Suezer, Yasemin, Sutter, Gerd   +10 more
core   +33 more sources

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications [PDF]

Vaccines, 2022
Modified vaccinia virus Ankara (MVA) is a promising viral vector for vaccine development. MVA is well studied and has been widely used for vaccination against smallpox in Germany. This review describes the history of the origin of the virus and its properties as a vaccine, including a high safety profile.
Olga Vladimirovna Orlova, Dina Viktorovna Glazkova, Elena Vladimirovna Bogoslovskaya, German Alexandrovich Shipulin, Sergey Mikhailovich Yudin   +4 more
openaire   +4 more sources

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus [PDF]

Biomedicines, 2021
There is a need to develop a highly effective vaccine against the emerging chikungunya virus (CHIKV), a mosquito-borne Alphavirus that causes severe disease in humans consisting of acute febrile illness, followed by chronic debilitating polyarthralgia and polyarthritis. In this review, we provide a brief history of the development of the first poxvirus
Juan García-Arriaza, Mariano Esteban, Daniel López   +2 more
openaire   +5 more sources

A vital gene for modified vaccinia virus Ankara replication in human cells [PDF]

Proceedings of the National Academy of Sciences, 2020
Vaccinia virus (VACV), the prototype orthopoxvirus, is the first live viral vaccine used to protect against smallpox, one of the most feared infectious diseases of humans (1). This outstanding achievement was possible because even as the various orthopoxviruses evolved and diversified they often retained major parts of their virion composition in ...
Sutter G.
openaire   +3 more sources

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps? [PDF]

Viruses, 2017
Modified vaccinia virus Ankara (MVA) is the vector of choice for human and veterinary applications due to its strong safety profile and immunogenicity in vivo. The use of MVA and MVA-vectored vaccines against human and animal diseases must comply with regulatory requirements as they pertain to environmental risk assessment, particularly the ...
Malachy Okeke, Arinze Okoli, Diana Diaz, Collins Offor, Taiwo Oludotun, Morten Tryland, Thomas Bøhn, Ugo Moens   +7 more
openaire   +6 more sources

Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles [PDF]

Journal of Virology, 2017
ABSTRACT There are currently no approved therapeutics or vaccines to treat or protect against the severe hemorrhagic fever and death caused by Ebola virus (EBOV). Ebola virus-like particles (EBOV VLPs) consisting of the matrix protein VP40, the glycoprotein (GP), and the nucleoprotein (NP) are highly immunogenic and protective in nonhuman ...
Schweneker, Marc, Laimbacher, Andrea S, Zimmer, Gert, Wagner, Susanne, Schraner, Elisabeth M, Wolferstätter, Michael, Klingenberg, Marieken, Dirmeier, Ulrike, Steigerwald, Robin, Lauterbach, Henning, Hochrein, Hubertus, Chaplin, Paul, Suter, Mark, Hausmann, Jürgen   +13 more
openaire   +4 more sources

Recombinant modified vaccinia virus Ankara-based malaria vaccines [PDF]

Expert Review of Vaccines, 2015
A safe and effective malaria vaccine is a crucial part of the roadmap to malaria elimination/eradication by the year 2050. Viral-vectored vaccines based on adenoviruses and modified vaccinia virus Ankara (MVA) expressing malaria immunogens are currently being used in heterologous prime-boost regimes in clinical trials for induction of strong antigen ...
Sarah Sebastian, Sarah C. Gilbert
openaire   +4 more sources

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer [PDF]

Human Vaccines & Immunotherapeutics, 2017
While interest in immunotherapies is renewed by the successful introduction of immune checkpoint blocking agent in the clinic, advances in genome sequencing are opening new possibilities in the design of increasingly personalized vaccines. Personalization of medicine can now be realistically contemplated at the single patient level. Unlike the previous
Kaïdre Bendjama, Eric Quemeneur
openaire   +5 more sources

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara [PDF]

BioTechniques, 2003
Caroline Staib, Marianne Löwel, Volker Erfle, Gerd Sutter   +3 more
openalex   +5 more sources

Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers [PDF]

AIDS Research and Human Retroviruses, 2017
We explored the duration of immune responses and the effect of a late third HIV-modified vaccinia virus Ankara (MVA) boost in HIV-DNA primed and HIV-MVA boosted Tanzanian volunteers. Twenty volunteers who had previously received three HIV-DNA and two HIV-MVA immunizations were given a third HIV-MVA immunization 3 years after the second HIV-MVA boost ...
Agricola Joachim, Agricola Joachim, Patricia L. Earl, Britta Wahren, Bernard Moss, Gunnel Biberfeld, Gunnel Biberfeld, Merlin L. Robb, Muhammad Bakari, Guido Ferrari, Patricia Munseri, Fred Mhalu, Valentina Liakina, Valentina Liakina, Said Aboud, Charlotta Nilsson, Charlotta Nilsson, Eligius Lyamuya, Eric Sandström, Gabriella Scarlatti, Teghesti Tecleab   +20 more
openaire   +4 more sources